Equities

Prime Medicine Inc

PRME:NMQ

Prime Medicine Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.24
  • Today's Change0.25 / 4.17%
  • Shares traded542.62k
  • 1 Year change-58.40%
  • Beta--
Data delayed at least 15 minutes, as of Jun 24 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. It has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.

  • Revenue in USD (TTM)591.00k
  • Net income in USD-204.50m
  • Incorporated2019
  • Employees234.00
  • Location
    Prime Medicine Inc60 First St.CAMBRIDGE 02141United StatesUSA
  • Phone+1 (617) 465-0013
  • Fax+1 (302) 655-5049
  • Websitehttps://primemedicine.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Perspective Therapeutics Inc-304.00k-48.91m679.85m116.00--2.58-----1.62-1.97-0.00923.92-0.0015-----2,620.69-24.10---25.46--------------0.0074--------------
CARGO Therapeutics Inc0.00-121.21m683.12m116.00--1.57-----2.91-2.910.009.48------0.00--------------------0.00-------139.67------
ProKidney Corp0.00-35.30m707.80m163.00---------0.567-0.5670.00-17.790.00----0.00-30.32------------------0.0004------67.17------
Praxis Precision Medicines Inc2.20m-125.38m713.40m82.00--2.41--325.01-15.91-15.910.239417.320.0126----26,768.29-71.89-74.04-83.56-85.12-----5,711.85-24,589.25----0.00------42.40---4.52--
Phibro Animal Health Corp999.56m13.16m714.48m1.92k54.302.6514.670.71480.32490.324924.686.671.032.426.37520,606.301.355.461.666.8330.3331.411.325.111.672.260.642742.993.783.59-33.69-13.5622.803.71
GeneDx Holdings Corp221.85m-135.02m718.10m1.00k--3.46--3.24-5.25-5.258.607.930.47219.167.27221,849.00-28.73---35.07--50.5711.50-60.86-121.102.99-130.270.2015---13.698.7267.98--7.77--
Prime Medicine Inc591.00k-204.50m718.98m234.00--2.95--1,216.56-2.17-2.170.00622.030.0019----2,525.64-65.09---70.51-------34,601.86------0.00-------39.52------
Arcturus Therapeutics Holdings Inc124.53m-107.30m739.28m180.00--2.80--5.94-4.02-4.024.669.810.2799--2.08691,811.10-24.12-19.66-31.37-24.90-----86.16-77.55----0.00---19.0360.31-417.95--14.44--
Stoke Therapeutics Inc7.85m-108.53m741.67m110.00--4.71--94.54-2.42-2.420.17473.020.0322--31.1971,318.18-44.57-31.62-51.70-33.92-----1,383.40-1,775.50----0.00---29.22---3.59--11.56--
Harrow Inc138.68m-31.33m743.02m315.00--12.27--5.36-0.9079-0.90794.091.710.54064.216.75440,244.40-12.21-10.86-13.79-12.7169.7770.75-22.59-15.352.75-0.33020.7536--46.9525.77-73.30--143.88--
Immunome Inc12.68m-232.03m746.01m55.00--2.60--58.82-5.49-5.490.42734.780.069----230,600.00-126.15-94.54-148.61-112.66-----1,829.44-1,403.15----0.00-------184.68--29.52--
Dianthus Therapeutics Inc3.22m-50.21m749.29m53.00--2.01--232.41-3.20-3.200.272112.700.0138----60,830.19-21.56-41.40-22.27-44.70-----1,557.51-12,132.27----0.00------43.04---57.21--
Nuvation Bio Inc0.00-68.87m753.87m159.00--1.12-----0.3146-0.31460.002.710.00----0.00-10.84-16.27-11.09-16.65------------0.00------27.25------
Data as of Jun 24 2024. Currency figures normalised to Prime Medicine Inc's reporting currency: US Dollar USD

Institutional shareholders

24.48%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 31 Mar 20245.99m4.99%
The Vanguard Group, Inc.as of 31 Mar 20245.72m4.77%
Nikko Asset Management Americas, Inc.as of 31 Mar 20243.36m2.80%
T. Rowe Price Investment Management, Inc.as of 31 Mar 20243.09m2.57%
BlackRock Fund Advisorsas of 31 Mar 20242.69m2.24%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20242.51m2.09%
Redmile Group LLCas of 31 Mar 20242.07m1.73%
Avidity Partners Management LPas of 31 Mar 20241.99m1.66%
Baker Bros. Advisors LPas of 31 Mar 20241.03m0.86%
Geode Capital Management LLCas of 31 Mar 2024916.86k0.76%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.